VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
February 20, 2020
- This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor.
- Pathology readouts are expected to shed light on the potential of VB-111 to turn ?cold? colorectal tumors ?hot.?